Aldeyra Therapeutics, Inc.: insider trades · United States · SEC (Form 4)

About Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics, Inc. (ticker: ALDX) is a U.S.-based biotechnology company listed on the NASDAQ, with corporate headquarters in Lexington, Massachusetts, United States. The company traces its roots back to Aldexa Therapeutics and adopted the Aldeyra Therapeutics name in 2014. It operates as a clinical-stage biotech focused on discovering and developing innovative therapies for immune-mediated diseases. ([ir.aldeyra.com](https://ir.aldeyra.com/faqs?utm_source=openai)) Aldeyra’s core scientific thesis is its proprietary RASP platform, which targets reactive aldehyde species, a family of endogenous molecules associated with inflammation and disease biology. Rather than relying on a conventional single-protein approach, the platform is designed to influence multiple inflammatory pathways. This gives Aldeyra a differentiated positioning among small-cap biotechs, although the investment case remains highly dependent on clinical validation and regulatory outcomes. ([aldeyra.com](https://www.aldeyra.com/about/?utm_source=openai)) The company’s lead asset is reproxalap, an investigational ophthalmic solution being developed for the signs and symptoms of dry eye disease. The program has been central to the equity story and has also been a source of volatility: the FDA accepted the NDA at one point, issued a Complete Response Letter in April 2025, and Aldeyra subsequently resubmitted the application in June 2025. In May 2025, the company also reported achievement of the primary endpoint in a Phase 3 dry eye chamber trial. Later regulatory updates confirmed that the FDA accepted the resubmission for review and assigned a new PDUFA target action date. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1341235/000121390025064869/ea0249257-8k_aldeyra.htm?utm_source=openai)) Beyond reproxalap, Aldeyra is advancing additional RASP modulators, including ADX-629, an oral candidate studied in systemic inflammatory conditions, and other early-stage programs. In 2025, the company also highlighted an expansion of the RASP platform into central nervous system diseases, signaling an attempt to broaden the pipeline beyond ophthalmology and into additional inflammatory or immune-linked indications. ([ir.aldeyra.com](https://ir.aldeyra.com/news-releases/news-release-details/aldeyra-therapeutics-advances-investigational-oral-rasp?utm_source=openai)) From a competitive standpoint, Aldeyra operates in a crowded biotech landscape where larger pharmaceutical companies and better-capitalized peers dominate commercialization and late-stage development. Its potential edge lies in the novelty of the RASP mechanism and the possibility of creating first-in-class or best-in-class assets. However, the company remains a development-stage organization with meaningful exposure to clinical trial readouts, FDA decisions, financing needs, and future commercialization execution. ([aldeyra.com](https://www.aldeyra.com/science-technology/?utm_source=openai))